The Incidence, Mortality, and Survival of Malignant Non-Small Cell Lung Cancer (NSCLC) in the United States: A Surveillance Epidemiology and End Results (SEER) 2000-2022 Database Analysis
Author(s)
Dimitrije Grbic, PhD (c), Filip Stanicic, PhD (c), Vlad Zah, DPhil.
ZRx Outcomes Research, Inc., Mississauga, ON, Canada.
ZRx Outcomes Research, Inc., Mississauga, ON, Canada.
OBJECTIVES: Investigating epidemiology and survival of non-small cell lung cancer (NSCLC) in the US using the most recent Surveillance, Epidemiology, and End Results (SEER) database released in April 2025.
METHODS: SEER*Stat was used to retrieve and analyze data from 17 US cancer registries (2000-2022). The target population consisted of patients with malignant NSCLC. Outcomes were crude incidence and mortality rates and survival.
RESULTS: There were 685,611 NSCLS patients. Most patients were 65+ years old (67.5%), males (52.4%), non-Hispanic Whites (75.5%), married (50.9%), from metropolitan counties (84.6%), and with $65,000-$90,000 annual household income (AHI) (46.1%). The incidence of NSCLC was 36.1 per 100,000 population. The incidence rates (per 100,000 population) were higher among patients with 65+ years (188.7), males (38.2), non-Hispanic Whites (50.1), from non-metropolitan counties (53.9), and with <$40,000 AHI (67.9). Incidence rates significantly decreased between 2000 and 2022 with -1.1 annual percent change (p<0.050). The mortality of NSCLC was 30.2 per 100,000 population. The mortality rates (per 100,000 population) were higher among patients with 65+ years (171.9), males (33.2), non-Hispanic Whites (42.3), from non-metropolitan counties (46.0), and with <$40,000 AHI (60.2). The survival of NSCLC was 49.2% at 1-year and 19.7% at 5-year endpoints. Survival rates decreased with aging and were higher among females than males (23.9% vs. 16.2% at 5-year endpoint). Regarding race/ethnicity, the 5-year survival rates were the lowest for non-Hispanic Blacks (16.3%) and non-Hispanic American Indians/Alaska Natives (18.0%). Patients from non-metropolitan counties had lower survival rates than those from metropolitan counties (17.4% vs. 20.2% at 5-year endpoint). Lower AHI was associated with shorter survival.
CONCLUSIONS: These findings show a concerning burden of NSCLC in the US. Although the annual incidence is slightly decreasing, less than 1 in 5 patients on average would survive a 5-year period. New effective treatments and social equality in healthcare are needed.
METHODS: SEER*Stat was used to retrieve and analyze data from 17 US cancer registries (2000-2022). The target population consisted of patients with malignant NSCLC. Outcomes were crude incidence and mortality rates and survival.
RESULTS: There were 685,611 NSCLS patients. Most patients were 65+ years old (67.5%), males (52.4%), non-Hispanic Whites (75.5%), married (50.9%), from metropolitan counties (84.6%), and with $65,000-$90,000 annual household income (AHI) (46.1%). The incidence of NSCLC was 36.1 per 100,000 population. The incidence rates (per 100,000 population) were higher among patients with 65+ years (188.7), males (38.2), non-Hispanic Whites (50.1), from non-metropolitan counties (53.9), and with <$40,000 AHI (67.9). Incidence rates significantly decreased between 2000 and 2022 with -1.1 annual percent change (p<0.050). The mortality of NSCLC was 30.2 per 100,000 population. The mortality rates (per 100,000 population) were higher among patients with 65+ years (171.9), males (33.2), non-Hispanic Whites (42.3), from non-metropolitan counties (46.0), and with <$40,000 AHI (60.2). The survival of NSCLC was 49.2% at 1-year and 19.7% at 5-year endpoints. Survival rates decreased with aging and were higher among females than males (23.9% vs. 16.2% at 5-year endpoint). Regarding race/ethnicity, the 5-year survival rates were the lowest for non-Hispanic Blacks (16.3%) and non-Hispanic American Indians/Alaska Natives (18.0%). Patients from non-metropolitan counties had lower survival rates than those from metropolitan counties (17.4% vs. 20.2% at 5-year endpoint). Lower AHI was associated with shorter survival.
CONCLUSIONS: These findings show a concerning burden of NSCLC in the US. Although the annual incidence is slightly decreasing, less than 1 in 5 patients on average would survive a 5-year period. New effective treatments and social equality in healthcare are needed.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EPH247
Topic
Epidemiology & Public Health, Real World Data & Information Systems
Disease
Oncology